{"id":45239,"date":"2026-04-07T09:47:08","date_gmt":"2026-04-07T09:47:08","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/45239\/"},"modified":"2026-04-07T09:47:08","modified_gmt":"2026-04-07T09:47:08","slug":"a-look-at-roche-holding-swxrop-valuation-after-recent-share-price-pullback","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/45239\/","title":{"rendered":"A Look At Roche Holding (SWX:ROP) Valuation After Recent Share Price Pullback"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.<\/p>\n

Roche Holding (SWX:ROP) has seen mixed share performance recently, with a 0.1% decline over the last day, a 1.2% gain over the past week, and declines over the past month and past 3 months.<\/p>\n

Over longer periods, the stock shows positive total returns over the past year, past 3 years, and past 5 years, giving investors a broader context for the more recent price moves.<\/p>\n

See our latest analysis for Roche Holding.<\/a><\/p>\n

Roche Holding\u2019s recent 6.8% 1 month share price decline contrasts with its 33.2% 1 year total shareholder return. This suggests some near term caution around the CHF318.0 share price, while the longer term picture remains constructive.<\/p>\n

If you are comparing Roche\u2019s profile with other healthcare names, this could be a good moment to scan 128 healthcare AI stocks<\/a><\/p>\n

So with Roche\u2019s recent 1 month pullback set against a 1 year total return above 30% and a CHF318 share price that sits below some valuation estimates, are you seeing a genuine opening, or is the market already pricing in future growth?<\/p>\n

Roche Holding\u2019s most followed narrative pegs fair value at CHF352, compared with the last close at CHF318, framing the current price against earnings and pipeline expectations.<\/p>\n

Giredestrant, fenebrutinib, Gazyva kidney indications, CT-388 in obesity and other post bar projects are aligned with long term shifts toward targeted, high impact therapies in oncology, neurology, immunology and metabolic disease, which can support mix quality and core operating margins if they convert to on market franchises.<\/p>\n

Read the complete narrative.<\/a><\/p>\n

Curious what kind of revenue path, margin profile and earnings multiple are baked into that CHF352 figure? The narrative leans on specific growth rates, profitability targets and a future valuation level that differs from today\u2019s market view, all tied to how successfully this pipeline and Diagnostics portfolio scale.<\/p>\n

Result: Fair Value of CHF352 (UNDERVALUED)<\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, the picture could shift quickly if China pricing pressure deepens in Diagnostics, or if key late stage projects like CT-388 or giredestrant hit setbacks.<\/p>\n

Find out about the key risks to this Roche Holding narrative.<\/a><\/p>\n

With sentiment split between opportunity and caution, this is a good moment to move quickly, review the underlying data yourself, and weigh up the 5 key rewards and 1 important warning sign<\/p>\n

If Roche has caught your eye, do not stop here. Use the Simply Wall St Screener to spot other opportunities that might suit your portfolio.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include ROP.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":18683,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[134,994,842,4667,1271],"class_list":{"0":"post-45239","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-roche","9":"tag-roche-holding","10":"tag-share-price","11":"tag-total-return","12":"tag-total-shareholder-return"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116362794979823962","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/45239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=45239"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/45239\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18683"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=45239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=45239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=45239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}